Psoriasis is a chronic autoimmune condition that speeds up the skin cell cycle, leading to inflammation, scaling, and visible lesions. There are five main types of psoriasis, including Plaque ... Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Understanding the Context

Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ... Yahoo: La La Anthony on Her Plaque Psoriasis: ‘It Doesn’t Have To Hold You Back' Add Yahoo as a preferred source to see more of our stories on Google. Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ... La La Anthony on Her Plaque Psoriasis: ‘It Doesn’t Have To Hold You Back' Essence: Living with Plaque Psoriasis as a Black Woman Isn’t Easy: Alisha Bridges Won’t Let the Disease Define Her Alisha Bridges, 36, knows what it feels like to be treated differently because of how she looks.

Key Insights

Since elementary school, Alisha has struggled with severe plaque psoriasis—a condition which causes ... Living with Plaque Psoriasis as a Black Woman Isn’t Easy: Alisha Bridges Won’t Let the Disease Define Her Seeking Alpha: Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ... Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill The American Journal of Managed Care: Zasocitinib Hits Phase 3 End Points in Plaque Psoriasis Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ... The National Law Review: Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill 84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Final Thoughts

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill